GOLDEN SUN SECURITIES·2026-03-08 12:24Investment Rating - The report maintains an "Increase" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector has experienced a decline of 2.78% this week, ranking 17th out of 31 sectors, while it has seen a slight increase of 0.1% year-to-date, ranking 24th out of 31 [9] - The 2026 government work report emphasizes the importance of the biopharmaceutical industry, categorizing it as a "new pillar industry," which indicates a strategic upgrade in its significance for economic growth and industrial upgrading [10][11] - The inclusion of brain-computer interfaces in the government work report marks a significant policy shift, enhancing market focus on related fields such as neural regulation and rehabilitation robotics [11] Company Dynamics - China Biopharmaceutical has entered an exclusive licensing agreement with Sanofi for the innovative drug Roflumilast, potentially earning up to $1.53 billion, including an upfront payment of $135 million [12] - Deking Pharmaceuticals has secured a global exclusive licensing agreement for ATG-201 with UCB, which includes an upfront payment of $80 million and potential milestone payments totaling approximately $1.1 billion [13] - East China Pharmaceutical has received approval to conduct clinical trials for DR30206, a fusion protein targeting multiple pathways for non-small cell lung cancer [14] - Yahui Pharmaceutical has achieved a commercial breakthrough with the approval of APL-1702 for treating cervical intraepithelial neoplasia [15] Investment Focus - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector as key investment opportunities [4][16]